From Medscape Diabetes & Endocrinology

European Association for the Study of Diabetes (EASD) 2016 Annual Meeting

September 12 - 16, 2016; Munich Germany

September 12 - 16, 2016 Munich Germany

Medscape at Booth S.05

EASD Half of All Type 1 Diabetes Develops After 30 Years of Age UK researchers find equal distribution of autoimmune-mediated diabetes below and above age 30 years, but after 30 this is "spotting a needle in a haystack," as cases are far exceeded by type 2 diabetes.
Medscape Medical News, September 20, 2016
EASD Libre 'Flash' Glucose Monitoring System Cuts Hypoglycemia Experts weigh the relative pros and cons of the new Freestyle Libre "Flash" Glucose Monitoring System, which seems to be gaining in popularity among diabetes patients in Europe.
Medscape Medical News, September 20, 2016
EASD First Data on GLP-1 Agonist/SGLT2 Inhibitor Combo in Diabetes Exenatide once weekly combined with daily dapagliflozin improved glycemic outcomes, BP, and weight loss more than each drug alone in DURATION-8, the first trial to examine a combination of these 2 agents.
Medscape Medical News, September 19, 2016

Top News From EASD 2016: Slideshow Highlights include the first full presentation of data from the SUSTAIN-6 trial plus renal results from LEADER and "eye-opening" data on type 1 diabetes.

Diabetes Drug Empagliflozin Cuts CV Deaths in Landmark EMPA-REG Trial For the first time ever, a type 2 diabetes drug has lowered the risk of cardiovascular death and, indeed, death from any cause, in a population of diabetics with established heart disease.
Medscape Medical News, Sep 17, 2015
After EMPA-REG: Docs Dissect Diabetes Study, Discuss Implications Doctors tried to make sense of the "unique" finding of the EMPA-REG OUTCOME study, which showed a mortality benefit for empagliflozin, but admitted the trial posed more questions than it answered.
Medscape Medical News, Sep 24, 2015
Capsaicin Patch Approved in EU for Diabetic Neuropathy Pain A capsaicin patch has been approved in the EU for use in diabetic neuropathy; a study reported at the EASD meeting showed the patch relieved pain and improved sleep among such patients.
Medscape Medical News, Sep 21, 2015
Home Use of 'Artificial Beta Cell' Works for 3 Months An "artificial beta-cell" system using already-available pumps and sensors improved glycemic control and reduced hypoglycemia in adults and children for 3 months in unrestricted and unsupervised real-world settings.
Medscape Medical News, Sep 18, 2015
Metformin Link to Vitamin B12 Deficiency, Neuropathy in Diabetes Researchers link 4 years of metformin use to a net worsening of peripheral neuropathy in type 2 diabetes, even after accounting for improvements from HbA1c lowering.
Medscape Medical News, Sep 25, 2015

Medscape Diabetes© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Expert Commentaries

Live Blog

News and Views from EASD 2016
Coverage of key advances and expert reactions as they happened at the meeting.

Medscape Board at the Podium

Per-Henrik Groop, MD, DMSc
Helsinki University Central Hospital, Finland
Presentation: OP 07 Novel insights into diabetic nephropathy
Date: September 13, 2016
Presentation: OP 11 Novel approaches to unravel glucose homeostasis in humans
Date: September 13, 2016
Presentation: OP 35 Novel genetics discoveries and phenotypic characterization
Date: September 15, 2016
Presentation: OP 36 Biomarkers and predictors of diabetic nephropathy
Date: September 15, 2016
Simon Heller, MB BChir, DM, FRCP
University of Sheffield School of Medicine; South Yorkshire, United Kingdom
Presentation: OP 02 insulin insights
Date: September 13, 2016
Chair of the Session: OP 14 Hypoglycaemia: The low down
Date: September 14, 2016
Arya Sharma, MD, PhD
PS 038 Determinants of beta cell function in humans and in non-human Primates
Presentation: PS 038 Determinants of beta cell function in humans and in non-human Primates
Date: September 13, 2016

Previous Coverage

Related Resources